Home›Research›Compare›Oxyntomodulin vs Tirzepatide
Peptide ComparisonOxyntomodulin vs Tirzepatide
Both are Metabolic peptides.
Oxyntomodulin
OXM
No providers listed yet
Tirzepatide
Dual GLP-1
Half-life: ~5 days (once-weekly dosing)
541 providers listed
Tirzepatide is FDA-approved, while Oxyntomodulin is investigational — the clearest structural difference between them.
Oxyntomodulin
Half-life
—
Tirzepatide
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Tirzepatide |
| Further along in FDA review | Tirzepatide |
| More provider options (0 vs 541) | Tirzepatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Oxyntomodulin
Tirzepatide
Oxyntomodulin
Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…
Oxyntomodulin reduces energy intake and adiposity in overweight and obese subjects
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity a…
Regulators of Appetite in Mammals - Old and New players.
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…
+5 more
About Oxyntomodulin
Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Oxyntomodulin
Class-based (investigational)
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Where to source these peptides
Oxyntomodulin
Browse directory →
Providers offeringTirzepatide
541 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.